Alzheimer-linked enzyme complex 'buckles up' for safe trip through the cell
Research News Release
EurekAlert! provides eligible reporters with free access to embargoed and breaking news releases.Eligibility Guidelines
EurekAlert! offers eligible public information officers paid access to a reliable news release distribution service.Eligibility Guidelines
EurekAlert! is a service of the American Association for the Advancement of Science.
A research team led by Wim Annaert (VIB-KU Leuven) uncovered the early assembly of gamma-secretase, a protein complex linked to numerous cellular processes including the development of Alzheimer's disease. In a first step, two dimeric subcomplexes are formed, which independently exit the ER and only afterwards assemble into a four-subunit complex. This 'buckle up' mechanism is thought to prevent premature assembly and activity.
A new paper published in the New England Journal of Medicine outlines a clinical trial, conducted in 392 people with psychosis associated with Alzheimer's disease, Parkinson's disease, Lewy body, frontotemporal, or vascular dementia. All participants were given pimavanserin for 12 weeks. Those who met a threshold of symptom improvement were then assigned to pimavanserin or placebo for up to 26 weeks.
New research sows that the same framework that can detect Alzheimer's disease in the cerebrospinal fluid of living patients can also detect other forms of neurodegeneration, like frontotemporal degeneration.
Scientists synthesized chemical compounds that can stop the degeneration of neurons in Alzheimer's, Parkinson's, and other severe brain pathologies.
In lab tests, Imperial researchers have created a metal-based molecule that inhibits the build-up of a peptide associated with Alzheimer's disease.
The main driver of Alzheimer's disease is excessive inflammation in the brain that is triggered by cells called astrocytes and microglia in response to high levels of amyloid beta deposits and tau tangles. New research reveals that a subset of astrocytes releases a molecule called interleukin-3 that instructs microglia to adopt a protective response and clear away amyloid beta deposits and tau tangles. Interleukin-3 may hold promise as a new therapeutic intervention in Alzheimer's disease.
Keeping your brain active in old age has always been a smart idea, but a new study suggests that reading, writing letters and playing card games or puzzles in later life may delay the onset of Alzheimer's dementia by up to five years. The research is published in the July 14, 2021, online issue of Neurology, the medical journal of the American Academy of Neurology.
A recently published study co-authored by University of Kentucky Sanders-Brown Center on Aging researcher Justin Miller, Ph.D., identifies 11 rare candidate variants for Alzheimer's disease. Researchers found 19 different families in Utah that suffered from Alzheimer's disease more frequently than what is considered normal.
Children with a devastating genetic disorder characterized by severe motor disability and developmental delay have experienced sometimes dramatic improvements in a gene therapy trial launched at UCSF Benioff Children's Hospitals.
A new study sheds light on how the specter of dementia and chronic pain reduce people's desire to live into older ages. Among Norwegians 60 years of age and older the desire to live into advanced ages was significantly reduced by hypothetical adverse life scenarios with the strongest effect caused by dementia and chronic pain. The paper is among the first to study Preferred Life Expectancy (PLE) based on hypothetical health and living conditions.